Improving care for patients with interstitial lung disease using remote monitoring.
Official title: Remote Evaluation and Surveillance of Patients with Interstitial Lung Disease (RESPOND-ILD): Transforming ILD Care Delivery with Remote Monitoring
Funded at University of California, San Francisco · NIH-10949539 · Data updated 2026-11-12
This study is looking at how a mix of in-person doctor visits and online check-ins can help people with interstitial lung disease (ILD) manage their condition better by using technology to keep track of their lung health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $189,332 |
| NIH project number | 1K23HL175213-01 |
| Project ID | NIH-10949539 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with interstitial lung disease who require ongoing monitoring and management of their condition.
✕Less likely to help
Patients with acute respiratory conditions or those not diagnosed with interstitial lung disease may not benefit from this research.
What this research studies
This research focuses on enhancing the management of interstitial lung disease (ILD) through a hybrid healthcare model that combines in-person visits with telehealth. By utilizing remote patient monitoring (RPM) technologies, such as spirometry and oximetry, the study aims to track disease progression and lung function more effectively. The approach leverages artificial intelligence to analyze RPM data, making it actionable for healthcare providers. This could lead to more timely interventions and better overall care for patients with ILD.
Why it matters
Potential benefit: If successful, this research could lead to improved monitoring and management of interstitial lung disease, resulting in better health outcomes for patients.
How similar studies have gone: Previous research has shown that remote monitoring can effectively track chronic diseases, indicating a promising potential for this approach in ILD management.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Farrand, Erica Davonne — University of California, San Francisco
- Study coordinator: Farrand, Erica Davonne
Related research
Other NIH-funded projects on the same topics.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.